Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy
Alba Rodríguez‐Martínez(Hospital Costa del Sol), María José Serrano(Instituto de Investigación Biosanitaria de Granada), Jordi Martorell‐Marugán(Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research), Diego de Miguel‐Pérez(Mount Sinai Health System), José A. Lorente(Universidad de Granada), Marta Legueren(Hospital Universitario Virgen de las Nieves), Hugh Ilyine(Genomics (United Kingdom)), Francisco G. Ortega(Universidad de Granada), Inmaculada Robles‐Fernandez(Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research), Christian Rolfo(Icahn School of Medicine at Mount Sinai), Pedro Carmona‐Sáez(Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research), M. Carmen Garrido-Navas(Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research), José Expósito(Hospital Universitario Virgen de las Nieves), José L. García-Puche(Hospital Universitario Virgen de las Nieves)
Cited by 182
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642